Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. United Therapeutics Corp shares valued at $3,904,496 were sold by EDGEMOND JAMES on Jun 09 ’25. At $325.37 per share, EDGEMOND JAMES sold 12,000 shares. The insider’s holdings dropped to 8,118 shares worth approximately $2.24 million following the completion of this transaction.
Also, EDGEMOND JAMES sold 12,000 shares, netting a total of over 3,909,893 in proceeds. Following the sale of shares at $325.82 each, the insider now holds 8,118 shares.
Before that, JAMES EDGEMOND had added 111,500 shares to its account. In a trade valued at $35,551,775, the Officer bought United Therapeutics Corp shares for $318.85 each.
As published in their initiating research note from Cantor Fitzgerald on June 02, 2025, United Therapeutics Corp [UTHR] has been an Overweight and the price target has been revised to $405. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in late April. As of April 21, 2025, BofA Securities has increased its “an Underperform” rating to a “Neutral” for UTHR. Earlier on July 11, 2024, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for UTHR stock which previously was a “an Overweight”.
Analyzing UTHR Stock Performance
During the last five days, there has been a drop of approximately -14.66%. Over the course of the year, United Therapeutics Corp shares have dropped approximately -21.64%. Shares of the company reached a 52-week high of $383.51 on 02/19/25 and a 52-week low of $266.98 on 04/09/25.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 270.80, which, if violated, would cause prices to drop to 265.13. In the upper region, resistance lies at 285.35. The next price resistance is at 294.23. RSI (Relative Strength Index) is 31.23 on the 14-day chart, showing neutral technical sentiment.
